Industry
Medical - Devices
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
Loading...
Open
3.44
Mkt cap
362M
Volume
775
High
3.45
P/E Ratio
-10.09
52-wk high
5.54
Low
3.43
Div yield
N/A
52-wk low
3.23
Portfolio Pulse from
November 07, 2024 | 12:15 am
Portfolio Pulse from
November 06, 2024 | 9:30 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 7:08 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 9:11 pm
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 8:35 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 12:08 pm
Portfolio Pulse from Avi Kapoor
May 08, 2024 | 5:38 pm
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 5:18 pm
Portfolio Pulse from Benzinga Insights
May 08, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
May 08, 2024 | 3:11 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.